

Biography – Wei Wang (王卫)

East China University of Science & Technology (华东理工大学药学院, 上海市新药设计重点实验室, 上海生物技术产业研究院, 和生物反应器国家重点实验室) and University of New Mexico



Wei Wang received his B.S. degree in chemistry in June 1988 from Nanjing Normal University, M.S. in organic chemistry in July 1993 from Shanghai Institute of Material Medica, CAS and PhD in organic chemistry in February 2000 at the North Carolina State University, Raleigh, NC, USA. He then spent about two years as a post-doc at the University of Arizona, Tucson, USA. Before he joined the Department of Chemistry & Chemical Biology, the University of New Mexico (UNM), Albuquerque, NM, USA, he worked as Principal Investigator at the Genomics Institute of the Novartis Research Foundation, San Diego, CA, USA from December 2001 to August 2003. He is Full Professor of Chemistry at the UNM. In June, 2011, he was recruited by East China University of Science & Technology (ECUST) as “Thousands of Talents Program” Professor and serve as the director of the Institute of Cancer research of ECUST. His group research interest includes 1) New synthetic methodology development, particular asymmetric synthesis and catalysts; 2) Total synthesis of biologically active compounds with unique structural and biological features; 3) Drug discovery and chemical biology/medicinal chemistry; and 4) Molecular recognition and imaging and drug delivery. He and his co-workers have published more than 160 papers including *Nature Commun.*, *Nature Mol. Biol.*, *J. Am. Chem. Soc.*, *Angew. Chem.*, *J. Biol. Chem.*, 1 book, 15 book chapters and 5 patents with H-index of 45. His research work has placed him in the top 5% of cited authors for journals in Chemistry. One of his patents has been licensed to the Aldrich Chemical Company, Inc., for his metal-free organo-catalysts technology, and one to license to the Andaman Therapeutics, Inc. in San Francisco for his bi-functional cancer drugs technology. The compound is undergoing clinical trials at UNM cancer center to validate their use as a new class of cancer therapeutics for several cancers including breast, prostate, lung, and rare and high mortality cancers. He has received several awards such as the Creative Award from the University of New Mexico (2012), the Chinese-American Chemistry & Chemical Biology Professors Association (CAPA) Distinguished Junior Faculty Award (2008) and the American Peptide Society the Bruce W. Erickson Young Investigator Award (2001).

Talk Title: N Powerful Organocatalytic Reactions for Organic Synthesis and Drug Discovery and Development